

# Evaluating comfort and handling of new patient extension line and bag connector for Peritoneal Dialysis (PD). A short-term, open controlled study.

<b>Submission date</b> 11/01/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 25/01/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 25/01/2007	<b>Condition category</b> Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mrs Christina Schönborg

**Contact details**  
Gambro  
Clinical Affairs  
Krokslätts Fabriker 32  
Möln dal  
Sweden  
SE-431 37

## Additional identifiers

**Protocol serial number**  
1443

## Study information

**Scientific Title**

**Study objectives**

Evaluate patient satisfaction in a first filed utilisation before final decision on product design.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics Committee at San Marino University Hospital in Genova , approved on 19/07/2006, ref: 0037753/06

**Study design**

Open, controlled, single center, comparative prospective pilot study

**Primary study design**

Interventional

**Study type(s)**

Quality of life

**Health condition(s) or problem(s) studied**

ESRD - End Stage Renal Disease

**Interventions**

Tested products: twist extension line combined with twist female connector on Gambrosol trio.

Reference products: current patient line (PDL 1201-8) and current Gambro CAPD system.

All patients will be treated in a CAPD program exchanging Gambrosol trio GEM 20U03 Ca 2,5 with twist for 3 to 5 exchanges/day following their physician's prescription on glucose concentration to be used. Evaluation on patient satisfaction will be done with a questionnaire at three times: before switch to twist, after two weeks on twist and at four weeks on tested products (end of study).

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Patient satisfaction on handling by comparing current system with new system, twist.

**Key secondary outcome(s)**

Collect safety data on new patient line.

**Completion date**

10/03/2007

**Eligibility**

**Key inclusion criteria**

1. Patients suffering from chronic renal failure
2. Age 18 years or older
3. Treated in a Continuous Ambulatory Peritoneal Dialysis (CAPD) program with Gambrosol trio (GEM 20U03 Ca 2,5)
4. Treated on CAPD for at least 24 months
5. Signed written informed consent to participate in the study

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

Not Specified

**Key exclusion criteria**

1. Pregnancy
2. HIV
3. Hepatitis
4. Participation in other studies during the study period if considered to cause interference with either of the studies
5. Treated in a haemodialysis program, patients with diagnosed abdominal pain not related with PD solution
6. Patients on night Automated Peritoneal Dialysis (APD)
7. Peritonitis within one month prior to the study
8. Presence of exit-site/tunnel infection or ongoing peritonitis
9. Impaired and /or disabled patients

**Date of first enrolment**

22/01/2007

**Date of final enrolment**

10/03/2007

**Locations****Countries of recruitment**

Italy

Sweden

## **Study participating centre**

**Gambro**  
Möln dal  
Sweden  
SE-431 37

## **Sponsor information**

### **Organisation**

Gambro (Sweden)

### **ROR**

<https://ror.org/05mw5ed57>

## **Funder(s)**

### **Funder type**

Industry

### **Funder Name**

Gambro (Sweden)

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration